| 1 |
|
A naturally occurring Tyr143Hisalpha~I~I~b mutation abolishes alpha~I~I~bbeta~3 function for soluble ligands but retains its ability for mediating cell adhesion and clot retraction: comparison with other mutations causing ligand-binding defects/
|
Kiyoi, T
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 2 |
|
A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2^-^/^- gammac^-^/^- double-mutant mice/
|
van Rijn, R. S
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 3 |
|
A novel anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis and tumor growth/
|
Yan, X
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 4 |
|
A novel EVI1 gene family, MEL1, lacking a PR domain (MEL1S) is expressed mainly in t(1; 3)(p36; q21)-positive AML and blocks G-CSF-induced myeloid differentiation/
|
Nishikata, I
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 5 |
|
A novel genetic leukocyte adhesion deficiency in subsecond triggering of integrin avidity by endothelial chemokines results in impaired leukocyte arrest on vascular endothelium under shear flow/
|
Alon, R
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 6 |
|
A novel missense mutation in the gamma-glutamylcysteine synthetase catalytic subunit gene causes both decreased enzymatic activity and glutathione production/
|
Hamilton, D
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 7 |
|
A novel MyD-1 (SIRP-1alpha) signaling pathway that inhibits LPS-induced TNFalpha production by monocytes/
|
Smith, R. E
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 8 |
|
A novel myeloid-like NK cell progenitor in human umbilical cord blood/
|
Perez, S. A
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 9 |
|
A novel strategy using single-chain antibody to show the importance of Bcl-2 in mast cell survival/
|
Cohen-Saidon, C
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 10 |
|
Neonatal or hepatocyte growth factor-potentiated adult gene therapy with a retroviral vector results in therapeutic levels of canine factor IX for hemophilia B/
|
Xu, L
|
W.B. Saunders Co., etc.]
|
2003
|
|
|
|
| 11 |
|
NEOPLASIA - Abnormal rearrangement within the a/d T-cell receptor locus in lymphomas from Atm-deficient mice/
|
Liyanage, M
|
W.B. Saunders Co., etc.]
|
2000
|
|
|
|
| 12 |
|
NEOPLASIA - Abolished angiogenicity and tumorigenicity of Burkitt lymphoma by interleukin-10/
|
Cervenak, L
|
W.B. Saunders Co., etc.]
|
2000
|
|
|
|
| 13 |
|
NEOPLASIA - A carboxy-terminal deletion mutant of Notch1 accelerates lymphoid oncogenesis in E2A-PBX1 transgenic mice/
|
Feldman, B J
|
W.B. Saunders Co., etc.]
|
2000
|
|
|
|
| 14 |
|
NEOPLASIA - A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL/
|
DiMartino, J F
|
W.B. Saunders Co., etc.]
|
2001
|
|
|
|
| 15 |
|
NEOPLASIA - A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts/
|
Press, O W
|
W.B. Saunders Co., etc.]
|
2001
|
|
|
|
| 16 |
|
NEOPLASIA - Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma/
|
Chesi, M
|
W.B. Saunders Co., etc.]
|
2001
|
|
|
|
| 17 |
|
NEOPLASIA - Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies/
|
Yamamoto, Y
|
W.B. Saunders Co., etc.]
|
2001
|
|
|
|
| 18 |
|
NEOPLASIA - Activation of apoptosis pathways in peripheral blood lymphocytes by in vivo chemotherapy/
|
Stahnke, K
|
W.B. Saunders Co., etc.]
|
2001
|
|
|
|
| 19 |
|
NEOPLASIA - Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3/
|
Wieder, T
|
W.B. Saunders Co., etc.]
|
2001
|
|
|
|
| 20 |
|
NEOPLASIA - Activation of the nitric oxide synthase pathway represents a key component of tumor necrosis factor--Related apoptosis-inducing ligand--Mediated cytotoxicity on hematologic malignancies/
|
Secchiero, P
|
W.B. Saunders Co., etc.]
|
2001
|
|
|
|
